News

Researchers from the University of Leeds have discovered that one of the body’s naturally occurring proteins is preventing 57 genes from operating normally in the brains of Huntington’s

The trials involved priming an immune response with three doses of a plasmid DNA (pDNA) vaccine over a two-month period, based on Vical’s proprietary DNA technology, and boosting

Risperdal (risperidone) is already indicated in adults for the treatment of schizophrenia, manic symptoms of acute manic or mixed episodes associated with bipolar I disorder, and for the

The designation has been given to Marqibo for the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia (ALL) in second relapse or who have failed two lines of

The drug, which is marketed by Roche in the EU, can now be prescribed to patients in England and Wales who have had an inadequate response to or

Under the terms of the agreement, Forest will pay Daiichi Sankyo an upfront payment of $20 million. Forest will enter into a co-promotion arrangement in the US, providing

The terms of the agreements include a $100 million payment to be made at closing, warrants for the purchase of up to one million shares of the company’s

The study, which included patients with and without depression, also showed greater improvements in patients taking Cymbalta (duloxetine HCl) than in those taking placebo in scores on the

German specialty pharmaceutical company Oncoscience is YM Bioscience’s European partner for the development of nimotuzumab, a humanized EGFR-targeting monoclonal antibody. In the first study, nimotuzumab and the current